GAT-1 selective GABA reuptake inhibitor

Plain-language summaryIntrigue 50 / 100

Tiagabine (Gabitril) is a selective inhibitor of the GAT-1 GABA transporter, the protein that pulls GABA back into nerve cells after release. By blocking GAT-1, the drug prolongs the time GABA remains in the synapse and amplifies inhibitory signaling. It was approved by the FDA in 1997 as add-on therapy for partial seizures. Clinical adoption was modest because it does not work well as monotherapy and has a narrow effective dose window. It saw some off-label use for anxiety and sleep, but a paradoxical risk of inducing seizures in patients without epilepsy when used at off-label doses earned it an FDA warning in 2005. Mostly a research tool now for studying GABA transporter pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

Canonical GAT-1 probe with solid bench utility but negligible novelty as a discovery target

Look, tiagabine is one of those compounds that earns its place in a research library not because anyone is racing to study it, but because you cant study GAT-1 biology without it. Thats the whole story. Developed at Novo Nordisk and approved by the FDA in 1997 under the name Gabitril, its been the canonical selective GAT-1 inhibitor for nearly three decades. The selectivity profile is genuinely impressive: greater than 100-fold preference for GAT-1 over GAT-2 and GAT-3. That kind of selectivity makes it the reference standard when you need to isolate GAT-1-dependent GABA reuptake from the rest of the transporter family.

What we like mechanistically is the specificity. GAT-1 is the dominant neuronal reuptake transporter, and tiagabine lets you ask precise questions about phasic versus tonic inhibition, about extracellular GABA pooling, about slow-wave sleep induction. Vyazovskiy and colleagues have used it productively in sleep slow-wave amplitude work. That’s real bench value. It’s not flashy, but it’s the kind of probe that generates clean, interpretable data in the right hands.

Here’s the thing though: the research-excitement case is weak. The mechanism is mature and single-target. GAT-1 inhibition is not a new idea; its not a dual mechanism, not a mitochondrial angle, not tied to any of the hot current targets in metabolic, longevity, or neuroplasticity research. You know exactly what youre getting, which is the point for tool use and a liability for frontier research. Nobody is writing a grant in 2026 with tiagabine as the exciting part of the story.

The translational picture is mixed. In epilepsy it works, thats settled, approved, replicated across phase 3. The off-label anxiety angle is genuinely complicated. The FDA issued warnings about new-onset seizures at off-label doses, with roughly a 1 percent incidence in non-epileptic patients. That safety signal killed most of the off-label enthusiasm and limits how freely investigators can extrapolate findings. It doesnt make it unusable in research, but it does mean translational upside outside the seizure indication is constrained.

We think tiagabine belongs in any library that takes GABA transporter biology seriously. It’s not a compound you pitch to a study section as exciting; it’s a compound you pull off the shelf when your experimental design requires isolating GAT-1 function. Useful, established, non-redundant in its specific niche. The score reflects that exactly: not a destination, but an indispensable tool for investigators working in the space.

Novelty: 22
Mechanism promise: 38
In-category differentiation: 58
Evidence quality: 72
Translational signal: 65
Research bench value: 72

Rationale Tiagabine scores on the strength of its unique probe identity as the only widely-used GAT-1-selective inhibitor, but its 1997 approval date, well-trodden mechanism, and seizure-risk liability in off-label use drag novelty and translational scores down hard. The high differentiation and bench-value scores reflect its irreplaceable role in GABA transporter work, not research excitement.

GAT-1 selective GABA reuptake inhibitor

A nipecotic acid derivative selective GABA reuptake inhibitor; the prototype GAT-1 transporter blocker.

Abstract

Tiagabine ((R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid; CAS 115103-54-3; molecular formula C20H25NO2S2; molecular weight 375.55) is a nipecotic acid derivative selective inhibitor of the GABA transporter GAT-1, developed at Novo Nordisk and approved by the FDA in 1997 under the trade name Gabitril. Mechanism: high-affinity inhibition of GAT-1 (the principal neuronal GABA reuptake transporter) prolongs synaptic GABA availability after release, enhancing GABA-A and GABA-B receptor activation. Selectivity for GAT-1 over GAT-2 and GAT-3 is greater than 100-fold. Plasma half-life is 7 to 9 hours; metabolism is via CYP3A4. Approved as adjunctive therapy in partial-onset seizures in patients aged 12 and older. Off-label use in generalized anxiety disorder has been complicated by FDA warnings of new-onset seizures in patients without epilepsy (incidence approximately 1 percent at off-label doses). Used as the canonical GAT-1 selective inhibitor in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-247Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: GAT-1 selective GABA reuptake inhibitor

Tiagabine

Abstract

Read the full monograph